• Skip to main content
  • Skip to footer

Oklahoma Medical Research Foundation | OMRF

OMRF is an independent, nonprofit biomedical research institute dedicated to discoveries that make a difference.

  • About
    • General Information
    • Disease Research
    • Education & Outreach
    • Events
    • Careers
    • Contact Us
  • Science
    • Scientist Directory
    • Research Programs
    • Research Centers
    • Core Facilities
    • Scientific Publications
    • Scientific Seminars
    • Technology Ventures
  • News
    • Media Resources
    • News Releases
    • Publications
    • On Your Health
    • Bodywork
  • Patients
    • Anti-Aging Studies
    • Lupus (SLE)
    • MBTPS1 Related Disorders
    • Multiple Sclerosis
    • Rheumatoid Arthritis
    • Sarcoidosis
    • Sjögren’s Disease
    • Other Autoimmune Disorders
  • Donate
    • Donate Now
    • Tax Credit
    • Planned Giving
    • Vehicle Donations
    • Why We Give
    • Your Gift at Work
    • Donor Recognition
    • Contact
Home - Diseases - OMRF scientists exploring novel breast cancer treatment

OMRF scientists exploring novel breast cancer treatment

November 16, 2009

Most breast cancer treatments fail to kill the small number of cancer stem cells that exist within the tumor. Consequently, those breast cancer stem cells can grow and multiply, resulting in additional tumors, both at the original site and in other areas of the body.

Led by Robert Floyd, Ph.D., OMRF scientists are studying a new method that may inhibit those cells’ ability to grow and spread. Floyd recently received a grant from the Department of Defense Congressionally Directed Medical Research Programs to fund the work for one year. His grant was one of only 86 awarded out of 1,546 applicants.

The project involves using a compound that Floyd and OMRF colleague Rheal Towner, Ph.D., developed for treating glioblastoma, a deadly form of brain cancer.

The OMRF research team found that by targeting a specific enzyme on the outer covering of breast cancer stem cells with the compound, they were able to interfere with the cell-to-cell signaling that encourages cells to multiply and metastasize.

“We tried the compound in breast cancer because of the similarities in the outer coating of brain cancer and breast cancer cells,” said Floyd, who holds the Merrick Foundation Chair in Aging Research at OMRF. “So far it seems to work in the same way in both forms of cancer, so our basic premise appears to be true.”

With the Department of Defense funding, the researchers will study the compound’s effectiveness in treating mice bred to develop breast cancer.

“This grant will allow us to continue our work on this promising project,” said Floyd. “No one has looked at blocking cancers by this method, so we’re excited to move ahead with this work that we hope will help stop a devastating disease.”

According to the American Cancer Society, approximately 1 in 8 women will develop breast cancer during their lifetimes. It is the second leading cause of cancer deaths in women. The ACS predicts that 192,000 new cases of breast cancer will be diagnosed in the U.S. this year.

Filed Under: Diseases, News Tagged With: breast, cancer, Floyd, Rheal, scientist-news, Towner

Before Footer

EEO/AA Employer/Vet/Disabled

Footer

  • Jobs
  • Directory
  • Donor Privacy Statement
  • Intranet
Facebook Twitter Instagram Linkedin

Subscribe to OMRF News
  • Contact
  • Careers
  • Donor Privacy
  • Intranet
OMRF Logo
OKLAHOMA MEDICAL RESEARCH FOUNDATION
825 NE 13th St.
Oklahoma City, OK 73104
(405) 271-6673
Charity navigatorUnited WayGive Smart OKCTop Workplace